FDA 483 - N-Molecular Inc. d.b.a. SOFIE - May 16, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
N-Molecular Inc. d.b.a. SOFIE in Haverhill, MA, a sterile PET drug manufacturer, was cited for significant deficiencies during an FDA inspection from May 8-16, 2019. The firm failed to follow written quality assurance procedures, including change control for critical GMP systems and product impact assessments for temperature excursions. Additionally, essential equipment, specifically an incubator used for sterility testing, was found unsuitable for its intended purpose due to temperature control issues and ice formation, with no backup available.
ID · 6a7f672b-f4c8-4a52-b1fb-07347108e883